Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02638935
Recruitment Status : Completed
First Posted : December 23, 2015
Last Update Posted : April 10, 2020
Sponsor:
Collaborator:
Siemens Medical Solutions
Information provided by (Responsible Party):
Michael Golatta, Heidelberg University

Tracking Information
First Submitted Date  ICMJE November 6, 2015
First Posted Date  ICMJE December 23, 2015
Last Update Posted Date April 10, 2020
Study Start Date  ICMJE February 2016
Actual Primary Completion Date March 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 25, 2017)
  • Standard chi-square test at a two-sided significance level of 5% to test the diagnostic accuracy of Virtual Touch Tissue Imaging Quantification (VTIQ) in the differentiation of BI-RADS® 3 and 4a lesions [ Time Frame: 2 years ]
    Hierarchical testing of the main statistical hypotheses H0_1, H0_2, H0_3 (test for H0_1 defines a gatekeeper) to evaluate the diagnostic accuracy of VTIQ in the differentiation of BI-RADS® 3 and 4a lesions: H0_1: The proportion of malignancies for group A (BI-RADS 4a, VTIQ ≥ cut-off) is less or equal to the proportion of malignancies for group B (BI-RADS 4a, VTIQ < cut-off). versus H1_1: The proportion of malignancies for group A is higher than the proportion of malignancies for group B.
  • Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_2 [ Time Frame: 2 years ]
    H0_2: The proportion of malignancies for group B (BI-RADS 4a, VTIQ < cut-off) is larger than or equal to 2%. versus H1_2: The proportion of malignancies for group B is smaller than 2%.
  • Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_3 [ Time Frame: 2 years ]
    H0_3: The proportion of malignancies for group D (BI-RADS 3, VTIQ < cut-off) is larger than or equal to 2%. versus H1_3: The proportion of malignancies for group D is smaller than 2%.
Original Primary Outcome Measures  ICMJE
 (submitted: December 18, 2015)
  • Standard chi-square test at a two-sided significance level of 5% to test the diagnostic accuracy of VTIQ in the differentiation of BI-RADS® 3 and 4a lesions [ Time Frame: 2 years ]
    Hierarchical testing of the main statistical hypotheses H0_1, H0_2, H0_3 (test for H0_1 defines a gatekeeper) to evaluate the diagnostic accuracy of VTIQ in the differentiation of BI-RADS® 3 and 4a lesions: H0_1: The proportion of malignancies for group A (BI-RADS 4a, VTIQ > cut-off) is less or equal to the proportion of malignancies for group B (BI-RADS 4a, VTIQ ≤ cut-off). versus H1_1: The proportion of malignancies for group A is higher than the proportion of malignancies for group B.
  • Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_2 [ Time Frame: 2 years ]
    H0_2: The proportion of malignancies for group B (BI-RADS 4a, VTIQ ≤ cut-off) is larger than or equal to 2%. versus H1_2: The proportion of malignancies for group B is smaller than 2
  • Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_3 [ Time Frame: 2 years ]
    H0_3: The proportion of malignancies for group D (BI-RADS 3, VTIQ ≤ cut-off) is larger than or equal to 2%. versus H1_3: The proportion of malignancies for group D is smaller than 2%.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 25, 2017)
  • Corresponding chi-square tests for descriptive analysis of Virtual Touch Tissue Imaging Quantification (VTIQ) in the assessment of BI-RADS® 3, 4b, 4c lesions [ Time Frame: 2 years ]
    Equivalent hypotheses as given for primary outcome measures can be formulated for the patients finally staged as BI-RADS® 3, 4b and 4c. These hypotheses will be analyzed with corresponding chi-square tests, where the resulting p-values are only interpreted descriptively: To assess whether ultrasonically visualized breast lesions, categorized as BI-RADS® 3/ 4b/ 4c with a VTIQ-measured shear velocity value of smaller than 3.5 m/s (37 kPa), show a lower malignancy rate than BI-RADS® 3/ 4b/ 4c with a VTIQ-measured shear velocity value of larger than or equal to 3.5 m/s (37 kPa).
  • BI-RADS® vs. BI-RADS® + Virtual Touch Tissue Imaging Quantification (VTIQ) [ Time Frame: 2 years ]
    Two logistic regression models including including BI-RADS® or BI-RADS® and VTIQ will be compared to test whether the probabilities for malignancies predicted with ultrasonically visualized breast lesions categorized as BI-RADS® differ from the probabilities for malignancies predicted with ultrasonically visualized breast lesions categorized as BI-RADS® and VTIQ-measured shear velocity.
  • Corresponding chi-square tests for descriptive analysis of the strain ratio in the differentiation of BI-RADS® 3, 4a, 4b or 4c lesions [ Time Frame: 2 years ]
    Equivalent hypotheses as given in H0_1 vs H1_1 can be formulated for the patients initially staged as BI-RADS® 3, 4b and 4c. These hypotheses will be analyzed with corresponding chi-square tests, where the resulting p-values are only interpreted descriptively to test whether for women with ultrasonically visualized breast lesions categorized as BI-RADS® 3, 4a, 4b or 4c respectively, the subgroup of women with a strain ratio smaller than or equal to 1 shows a lower malignancy rate than the subgroup of women with a strain ratio of larger than 1.
  • Robust regression models to test the INTRA-RATER reliability for the original continuous scale [ Time Frame: 2 years ]
    Robust regression models (Passing-Bablok-regression, orthogonal regression) and Bland-Altman Plots will be used for pairwise comparison of the continuous values between raters, where a slope of 1 and an intercept of 0 indicates agreement.
  • Cohens's Kappa to test the INTRA-RATER reliability for the dichotomized values [ Time Frame: 2 years ]
  • Robust regression models to test the INTER-RATER reliability for the original continuous scale [ Time Frame: 2 years ]
    Robust regression models (Passing-Bablok-regression, orthogonal regression) and Bland-Altman Plots will be used for pairwise comparison of the continuous values between raters, where a slope of 1 and an intercept of 0 indicates agreement.
  • Cohens's Kappa to test the INTER-RATER reliability for the dichotomized values [ Time Frame: 2 years ]
  • Descriptive analysis of predictive factors of the continuous VTIQ-value [ Time Frame: 2 years ]
    Thereby the following factors will be examined: Subject-related factors:
    • Skin - breast lesion surface depth (cm)
    • Quality factor (color coded scale) within the lesion
    • Breast density/ Tissue composition (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture)
    • Lesion size in B-mode (cm)
    • Normal fatty tissue shear wave velocity (Ratio between measurement in the fatty tissue and in the lesion)
    • Pathology (fibroadenoma, lipoma, atypia, cyst condense, "non special type" (NST), invasive lobular carcinoma (ILC), invasive tubular carcinoma (ITC), carcinoma with medullary features, papillary cancer, ductal carcinoma in situ (DCIS), others)
    • Grading (G1, G2, G3, Gx)
    • Immunohistology (estrogen receptor (ER) status positive/ negative, progesterone receptor (PgR) status positive/ negative, human epidermal growth factor receptor 2 (HER2-neu) status positive/ negative, Ki-67 status (%))
  • Skin to breast lesion surface depth (cm) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the skin - breast lesion surface depth (cm).
  • Quality factor within the lesion assessed using a color coded scale [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the Quality factor (color coded scale) within the lesion.
  • Breast density/ tissue composition assessed using the morphologic characteristics on US (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the breast density/ tissue composition (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture).
  • Lesion size in B-mode Ultrasound (in cm) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the lesion size in B-mode (cm).
  • Normal fatty tissue shear wave velocity (ratio between measurement in the fatty tissue and in the lesion) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the normal fatty tissue shear wave velocity (ratio between measurement in the fatty tissue and in the lesion).
  • Pathology (fibroadenoma, lipoma, atypia, cyst condense, "non special type" (NST), invasive lobular carcinoma (ILC), invasive tubular carcinoma (ITC), carcinoma with medullary features, papillary cancer, ductal carcinoma in situ (DCIS), others) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the pathology (fibroadenoma, lipoma, atypia, cyst condense, "non special type" (NST), invasive lobular carcinoma (ILC), invasive tubular carcinoma (ITC), carcinoma with medullary features, papillary cancer, ductal carcinoma in situ (DCIS), others).
  • Grading (G1, G2, G3, Gx) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the grading (G1, G2, G3, Gx).
  • Immunohistology (estrogen receptor (ER) status positive/ negative, progesterone receptor (PgR) status positive/ negative, human epidermal growth factor receptor 2 (HER2-neu) status positive/ negative, Ki-67 status (%)) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the immunohistology (estrogen receptor (ER) status positive/ negative, progesterone receptor (PgR) status positive/ negative, human epidermal growth factor receptor 2 (HER2-neu) status positive/ negative, Ki-67 status (%)).
  • Cohens's Kappa to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment) [ Time Frame: 2 years ]
    Local (BI-RADS® given at each site) and central expert BI-RADS® assessment will be compared (BI-RADS® assessment and assessment of the variables leading to the BI-RADS® value separately). To test the inter-rater reliability of BI-RADS® Assessment Cohens' Kappa will be calculated.
  • Interclass correlation coefficient (ICC) values to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment) [ Time Frame: 2 years ]
    Local (BI-RADS® given at each site) and central expert BI-RADS® assessment will be compared (BI-RADS® assessment and assessment of the variables leading to the BI-RADS® value separately). To test the inter-rater reliability of BI-RADS® Assessment ICC values will be calculated.
  • BI-RADS® vs. histological results [ Time Frame: 2 years ]
    To compare the BI-RADS® assessments with the histological results, the malignancy rates will be computed separately for each BI-RADS® value. It will then be checked whether these rates lie within the given intervals. Furthermore, the likelihood of malignancy estimated by the experts will be examined using receiver operating curve (ROC) and area under the curve (AUC).
  • Chi-square test to examine whether the cut-off value of ≥ 3.5 m/s (37kPa) might be increased by increasing the cut-off value step-by-step by a small amount and repeat the primary analysis [ Time Frame: 2 years ]
    We will increase the cut-off value step-by-step by a small amount and repeat the primary analysis (using a chi-square test). We stop the testing procedure as soon as the p-value is above the significance level (0.05). This analysis is, obviously, only an explorative one and has no confirmatory value.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 18, 2015)
  • Corresponding chi-square tests for descriptive analysis of VTIQ in the assessment of BI-RADS® 3, 4b, 4c lesions [ Time Frame: 2 years ]
    Equivalent hypotheses as given for primary outcome measures can be formulated for the patients finally staged as BI-RADS® 3, 4b and 4c. These hypotheses will be analyzed with corresponding chi-square tests, where the resulting p-values are only interpreted descriptively.
  • BI-RADS® vs. BI-RADS® + VTIQ [ Time Frame: 2 years ]
    Two logistic regression models including including BI-RADS® or BI-RADS® and VTIQ will be compared to test whether the probabilities for malignancies predicted with ultrasonically visualized breast lesions categorized as BI-RADS® differ from the probabilities for malignancies predicted with ultrasonically visualized breast lesions categorized as BI-RADS® and VTIQ-measured shear velocity.
  • Corresponding chi-square tests for descriptive analysis of the strain ratio in the differentiation of BI-RADS® 3, 4a, 4b or 4c lesions [ Time Frame: 2 years ]
    Equivalent hypotheses as given in H0_1 vs H1_1 can be formulated for the patients initially staged as BI-RADS® 3, 4b and 4c. These hypotheses will be analyzed with corresponding chi-square tests, where the resulting p-values are only interpreted descriptively to test whether for women with ultrasonically visualized breast lesions categorized as BI-RADS® 3, 4a, 4b or 4c respectively, the subgroup of women with a strain ratio smaller than or equal to 1 shows a lower malignancy rate than the subgroup of women with a strain ratio of larger than 1.
  • Robust regression models to test the INTRA-RATER reliability for the original continuous scale [ Time Frame: 2 years ]
    Robust regression models (Passing-Bablok, orthogonal regression) and Bland-Altman Plots will be used for pairwise comparison of the continuous values between raters, where a slope of 1 and an intercept of 0 indicates agreement.
  • Cohens's Kappa to test the INTRA-RATER reliability for the dichotomized values [ Time Frame: 2 years ]
  • Robust regression models to test the INTER-RATER reliability for the original continuous scale [ Time Frame: 2 years ]
    Robust regression models (Passing-Bablok, orthogonal regression) and Bland-Altman Plots will be used for pairwise comparison of the continuous values between raters, where a slope of 1 and an intercept of 0 indicates agreement.
  • Cohens's Kappa to test the INTER-RATER reliability for the dichotomized values [ Time Frame: 2 years ]
  • Descriptive analysis of predictive factors of the continuous VTIQ-value [ Time Frame: 2 years ]
    Thereby the following factors will be examined: Subject-related factors:
    • Skin - breast lesion surface depth (cm)
    • Quality factor (color coded scale) within the lesion
    • Breast density/ Tissue composition (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture)
    • Lesion size in B-mode (cm)
    • Normal fatty tissue shear wave velocity (Ratio between measurement in the fatty tissue and in the lesion)
    • Pathology (fibroadenoma, lipoma, atypia, cyst condense, NST cancer (NST = "non special type", ILC (= invasive lobular cancer), ITC (= invasive tubular cancer), carcinoma with medullary features, papillary cancer, DCIS, others)
    • Grading (G1, G2, G3, Gx)
    • Immunhistology (ER status positive/ negative, PgR status positive/ negative, HER2-neu status positive/ negative, Ki-67 status (%))
  • Skin to breast lesion surface depth (cm) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the skin - breast lesion surface depth (cm)
  • Quality factor within the lesion assessed using a color coded scale [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the Quality factor (color coded scale) within the lesion
  • Breast density/ tissue composition assessed using the morphologic characteristics on US (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the Breast density/ Tissue composition (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture)
  • Lesion size in B-mode Ultrasound (in cm) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the lesion size in B-mode (cm)
  • Normal fatty tissue shear wave velocity (ratio between measurement in the fatty tissue and in the lesion) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the normal fatty tissue shear wave velocity (Ratio between measurement in the fatty tissue and in the lesion)
  • Pathology (fibroadenoma, lipoma, atypia, cyst condense, NST cancer (NST = "non special type", ILC (= invasive lobular cancer), ITC (= invasive tubular cancer), carcinoma with medullary features, papillary cancer, DCIS, others) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the pathology (fibroadenoma, lipoma, atypia, cyst condense, NST cancer (NST = "non special type", ILC (= invasive lobular cancer), ITC (= invasive tubular cancer), carcinoma with medullary features, papillary cancer, DCIS, others)
  • Grading (G1, G2, G3, Gx) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the grading (G1, G2, G3, Gx) - Immunhistology (ER status positive/ negative, PgR status positive/ negative, HER2-neu status positive/ negative, Ki-67 status (%))
  • Immunhistology (ER status positive/ negative, PgR status positive/ negative, HER2-neu status positive/ negative, Ki-67 status (%)) [ Time Frame: 2 years ]
    For descriptive analysis of predictive factors of the continuous VTIQ-value, different univariable und multivariable linear regression models will be evaluated and compared. Thereby one factor to be examined is the immunhistology (ER status positive/ negative, PgR status positive/ negative, HER2-neu status positive/ negative, Ki-67 status (%))
  • Cohens's Kappa to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment) [ Time Frame: 2 years ]
    Local (BI-RADS® given at each site) and central expert BI-RADS® assessment will be compared (BI-RADS® assessment and assessment of the variables leading to the BI-RADS® value separately). To test the inter-rater reliability of BI-RADS® Assessment Cohens' Kappa will be calculated.
  • ICC values to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment) [ Time Frame: 2 years ]
    Local (BI-RADS® given at each site) and central expert BI-RADS® assessment will be compared (BI-RADS® assessment and assessment of the variables leading to the BI-RADS® value separately). To test the inter-rater reliability of BI-RADS® Assessment ICC values will be calculated.
  • BI-RADS® vs. histological results [ Time Frame: 2 years ]
    To compare the BI-RADS® assessments with the histological results, the malignancy rates will be computed separately for each BI-RADS® value. It will then be checked whether these rates lie within the given intervals. Furthermore, the likelihood of malignancy estimated by the experts will be examined using ROC and AUC.
  • Chi-square test to examine whether the cut-off value of 3.5 m/s (37kPa) might be increased by increasing the cut-off value step-by-step by a small amount and repeat the primary analysis [ Time Frame: 2 years ]
    We will increase the cut-off value step-by-step by a small amount and repeat the primary analysis (using a chi-square test). We stop the testing procedure as soon as the p-value is above the significance level (0.05). This analysis is, obviously, only an explorative one and has no confirmatory value.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions
Official Title  ICMJE Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions: Can Patient Selection for Biopsy be Improved? - A Confirmatory Multi-Center-Study
Brief Summary The primary aim of this study is to evaluate if VTIQ in addition to BI-RADS® categorization can improve the diagnostic accuracy with respect to detection of malignancies, in particular for BI-RADS® categories 3 and 4a. The idea of the study is to restage all patients in categories 3 and 4a according to a predefined VTIQ cut-off value of ≥ 3.5 m/s (37 kPa).
Detailed Description

Elastography is a method of imaging tissue stiffness. It is based on shear wave velocity information that can be mapped to create an image of the stiffness in the region of interest.

Sonoelastography is used to differentiate benign from malignant lesions since malignant lesions alter tissue elasticity.

Adding Shear Wave elastographic features to BI-RADS® feature analysis- especially in lesions scored BI-RADS® 3 and 4a- improved specificity of breast US mass assessment without loss of sensitivity.

The BI-RADS® categories are defined by the risk for a malignant lesion varying from benign BI-RADS® 2 lesions, up to a 2% malignancy rate in BI-RADS® 3 and 2- 95% in BI-RADS® 4 (4a 2-10%; 4b 10-50%; 4c 50-95%). Based on these probabilities, biopsies are recommended for BI-RADS® 4 and 5 lesions and short-term follow-up examinations for BI-RADS® 3. Consequently, up to 2% of the in Ultrasound visible breast cancers are not directly detected as such and put into the BI-RADS® 3 category. In contrast, in the BI-RADS® 4a category more than 90% of the biopsies are unnecessary.

The main aim of the confirmatory study is to use Virtual Touch Tissue Imaging Quantification in order to reduce unnecessary benign biopsies without a reduction of the number of detected cancers.

This multi-center study is planned to involve 12 sites in 7 countries. Recruitment started at the first sites in February 2016. Recruitment takes place in the course of the patient's routine visit at a certified breast unit. All study participants will receive VTIQ in addition to standard ultrasound.

Enrollment goal is a total of 1000 cases, split into groups of a minimum of n= 300 BI-RADS® 3, n= 400 BI-RADS® 4a, n= 100 BI-RADS® 4b, n= 100 BI-RADS® 4c. All patients will be documented in a screening list. Monitoring will be performed by the Coordination Center for Clinical Trials (KKS Heidelberg). Completeness, validity and plausibility of data will be checked in time of data entry (edit-checks) and using validating programs, which will generate queries. The investigator or the designated representatives are obliged to clarify or explain the queries. If no further corrections are to be made in the database it will be closed and used for statistical analysis. All data management procedures will be carried out on validated systems and according to the current Standard Operating Procedures (SOPs) of the Institute of Medical Biometry and Informatics.

The standard BI-RADS® Ultrasound (US) category (BI-RADS® 3-4c) and VTIQ values will be correlated with the histological result. Additionally, local (BI-RADS® given at each site) and central expert BI-RADS® assessment will be compared (BI-RADS® assessment and assessment of the variables leading to the BI-RADS® value separately) to assess the inter-rater reliability. In addition, the BI-RADS® assessments will be compared with the histological results.

The variable "measurement lesion (in m/s)" is derived from three VTIQ measurements as follows:

I. For confirmatory analysis of primary objectives an algorithm was established,

  1. using the first measurement for analysis if the value is smaller than 2.5 m/s or if the value is larger than 4.5 m/s. If the first measurement is smaller than 2.5 m/s, the lesion can be considered benign and no further diagnostics is needed. If the lesion is larger than 4.5 m/s the lesion should be considered suspicious and further diagnostics is required.
  2. requiring two additional measurements (in total three measurements) if the first measurement is in the range of ≥ 2.5 m/s to ≤ 4.5 m/s. In this case the average of all three measurements is used for analysis.

II. For descriptive analysis other options for derivation of this variable from the three VTIQ measurements will be calculated for discussion:

  1. First measurement only
  2. Average of all three measurements
  3. Median of all three measurements
  4. Maximum of all three measurements

In conjunction with the maximum VTIQ shear wave velocity the quality display will be used to aid in the classification of lesions as malignant or benign as follows:

  1. If the shear wave velocity ≥ the cut-off value (3.5 m/s), the lesion is considered potentially malignant, regardless of the outcome of the quality factor
  2. If a lesion or lesion rim has a completely high quality factor (all green) and a shear wave velocity < the cut-off value (3.5 m/s), the lesion is considered benign.
  3. If a lesion or lesion rim has mixed high and low quality factors (there are areas with low quality within the mass) and the only area of high quality (green) has a shear wave velocity < the cut-off value (3.5 m/s), then the lesion is indeterminate and malignancy cannot be excluded.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Condition  ICMJE Breast Neoplasms
Intervention  ICMJE Device: Ultrasound- Virtual Touch Tissue Imaging Quantification
Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
Other Names:
  • Elasticity Imaging
  • VTIQ
  • Elastography
  • Ultrasound
  • ARFI
Study Arms  ICMJE
  • BI-RADS 3
    Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
    Intervention: Device: Ultrasound- Virtual Touch Tissue Imaging Quantification
  • BI-RADS 4a
    Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
    Intervention: Device: Ultrasound- Virtual Touch Tissue Imaging Quantification
  • BI-RADS 4b
    Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
    Intervention: Device: Ultrasound- Virtual Touch Tissue Imaging Quantification
  • BI-RADS 4c
    Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
    Intervention: Device: Ultrasound- Virtual Touch Tissue Imaging Quantification
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 9, 2020)
1304
Original Estimated Enrollment  ICMJE
 (submitted: December 18, 2015)
1000
Actual Study Completion Date  ICMJE March 2019
Actual Primary Completion Date March 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Female
  • Age ≥18 years
  • Patients with a lesion ≥ 0.5 cm in largest diameter size, initially scored BI-RADS® 3, 4a, 4b or 4c in B-mode ultrasound
  • Informed consent about histological examination (core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery) has already been given in the course of clinical routine
  • Signed informed consent of study participation

Exclusion Criteria:

  • Pregnant or lactating women
  • Women with breast implants on the same side as the lesion
  • Women that underwent local radiation or chemotherapy within the last 12 months
  • Women with history of breast cancer or breast surgery in the same quadrant
  • Lesions in or close to scar tissue (< 1cm)
  • Skin lesions or lesions that have been biopsied previously
  • Lesion larger than 4 cm in the longest dimension
  • No lesion should be included when more than 50% of the lesion is further down than 4 cm beneath the skin level.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Germany,   Japan,   Netherlands,   Portugal,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02638935
Other Study ID Numbers  ICMJE VTIQ
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Michael Golatta, Heidelberg University
Study Sponsor  ICMJE Heidelberg University
Collaborators  ICMJE Siemens Medical Solutions
Investigators  ICMJE
Principal Investigator: Michael Golatta, PD Dr. med., MHBA University of Heidelberg, Department of Gynecology, Breast Unit
PRS Account Heidelberg University
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP